Search Results
Your search for ,kEY matches 7151 pages
Showing 801 - 850Early-Stage Nonrectal Mismatch Repair–Deficient Tumors Respond to Neoadjuvant PD-1 Blockade, Facilitating Nonoperative Management
Mismatch repair–deficient (dMMR) tumors beyond those in the rectum may respond to PD-1 blockade in the neoadjuvant setting, offering the option of organ preservation in early-stage cancer regardless of the tumor type, researchers from Memorial Sloan Kettering (MSK) Cancer Center reported at the...
Together, We’re Building a Better Future for People With Cancer and for Our Profession
For more than 25 years, my goal as a community oncologist has been to ensure that all patients have access to the highest-quality cancer care. This is the future I stood for when I became ASCO’s 61st President and what I know our more than 50,000 members stand for. And I believe we will get there...
The Power of Translational Science to Transform the Lives of Patients Worldwide
Despite a 30-year history as an ASCO volunteer, for Eric J. Small, MD, FASCO, this past year as President-Elect has opened new perspectives on the organization he will soon lead as ASCO’s 62nd President, effective during the 2025 ASCO Annual Meeting, May 30–June 3, 2025, in Chicago. After serving...
Early-Phase Trial Shows Activity and Safety of Zongertinib in Previously Treated HER2-Mutant NSCLC
Zongertinib, an investigational oral, HER2-selective, EGFR-sparing tyrosine kinase inhibitor, elicited durable responses and demonstrated clinical benefit in patients with advanced, previously treated, HER2-mutant non–small cell lung cancer (NSCLC), according to data presented by John V. Heymach,...
Inavolisib-Based Regimen in PIK3CA-Mutated, HR-Positive, HER2-Negative Advanced Breast Cancer
New findings from the phase III INAVO120 trial showed that adding inavolisib to palbociclib and fulvestrant may help extend survival and delay the time until treatment with chemotherapy in previously treated patients with PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer. The...
GLP-1 RAs May Lower Risk of Obesity-Related Cancers
Studies have shown that having overweight or obesity increases the risk of developing more than a dozen cancers, including meningioma; multiple myeloma; and esophageal, thyroid, breast, gallbladder, stomach, liver, pancreatic, kidney, ovarian, uterine, and colorectal cancers. The presence of excess ...
Extensive-Stage SCLC: Lurbinectedin and Atezolizumab
Results from a global phase III clinical trial found that maintenance therapy with a combination of the alkylating agent lurbinectedin and the PD-L1 inhibitor atezolizumab improved survival in some patients with extensive-stage small cell lung cancer (SCLC) compared with maintenance therapy with...
Revealing Critical Insights for Precision Medicine in Patients With Metastatic Prostate Cancer
Investigators may have uncovered key differences in tumor biology but similarities in survival outcomes in instances of equal access to care between non-Hispanic Black and non-Hispanic White men with metastatic prostate cancer, according to a recent study published by Valle et al in JAMA Network...
Addition of Tocilizumab to Nab-Paclitaxel and Gemcitabine in First-Line Treatment of Advanced Pancreatic Cancer
In a phase II trial reported in the Journal of Clinical Oncology, Chen et al attempted to determine whether there is a benefit to adding tocilizumab to nab-paclitaxel and gemcitabine in the first-line treatment of patients with advanced pancreatic cancer. Study Details In the open-label trial, 141...
Association Between Risk-Reducing Surgeries and Survival in Young BRCA Carriers With Breast Cancer
In an international cohort study reported in The Lancet Oncology, Blondeaux et al evaluated whether both risk-reducing mastectomy and risk-reducing salpingo-oophorectomy were associated with improved survival among women aged 40 or younger who have invasive breast cancer with germline BRCA1/2...
p53 Dysfunction in Myelodysplastic Syndromes
In a study reported in the Journal of Clinical Oncology, Zampini et al identified a proportion of patients with myelodysplastic syndromes who had nonmutational TP53 but p53 dysfunction, which was associated with poor disease outcomes. Study Details The study involved data from a cohort of 6,204...
Anlotinib Plus Penpulimab in First-Line Treatment of Unresectable Hepatocellular Carcinoma
In a Chinese phase III trial (APOLLO) reported in The Lancet Oncology, Zhou et al evaluated whether the combination of the multikinase inhibitor anlotinib and the PD-1 inhibitor penpulimab improved progression-free survival and overall survival vs sorafenib in first-line treatment of unresectable...
Gabapentin May Extend Survival in Patients With Glioblastoma
Investigators have found that the antiseizure/pain drug gabapentin may be associated with improved survival in patients with glioblastoma, according to a recent study published by Bernstock et al in Nature Communications. Background With about 12,000 new cases diagnosed annually in the United...
Former President Biden Diagnosed With Metastatic Prostate Cancer
According to his office, Former President Joseph R. Biden Jr has been diagnosed with an “aggressive” type of prostate cancer that has spread to his bones. The New York Times reported that Mr. Biden’s cancer “is characterized by a Gleason score of 9 with metastasis to the bone.” The American Cancer...
Chemotherapy-Free Neoadjuvant Therapy for HER2-Enriched Early Breast Cancer
In a German phase II trial (WSG-KEYRICHED-1) reported in The Lancet Oncology, Kuemmel et al evaluated whether chemotherapy-free neoadjuvant therapy with pembrolizumab plus trastuzumab/pertuzumab showed activity in patients with HER2-enriched early breast cancer. As stated by the investigators:...
Antimicrobial Resistance in Outpatients With Cancer
In a U.S. multicenter retrospective cohort study reported in The Lancet Oncology, Gupta et al evaluated whether antimicrobial resistance was more common in pathogenic bacterial isolates from outpatients with cancer than in outpatients without cancer. Study Details The study involved data from the...
Reduced-Dose Chemoradiotherapy for Early-Stage Anal Cancer
In a UK phase II trial (PLATO-ACT4) reported in The Lancet Oncology, Gilbert et al evaluated whether short-term results showed good complete response rates with both standard-dose and reduced-dose chemoradiotherapy in patients with localized squamous cell carcinoma of the anus. Study Details In the ...
Novel Prediction Model for Hearing Loss From Chemotherapy in Pediatric Patients With Cancer
In a study reported in the Journal of Clinical Oncology, Millstein et al attempted to develop a predictive model—Pediatric Holistic Evaluation of Auditory Risk (PedsHEAR)—for hearing loss associated with cisplatin chemotherapy in children and adolescents with cancer. Study Details PedsHEAR was...
Second-Line Endocrine Therapy With/Without Palbociclib Rechallenge in HR-Positive, HER2-Negative Advanced Breast Cancer
In a phase II trial (PALMIRA) reported in the Journal of Clinical Oncology, Llombart-Cussac et al evaluated whether palbociclib rechallenge with second-line alternative endocrine therapy may improve progression-free survival vs second-line alternative endocrine therapy alone. Study Details In the...
Retifanlimab-dlwr Approved for Anal Cancer
On May 15, the U.S. Food and Drug Administration (FDA) approved retifanlimab-dlwr (Zynyz), a PD-1–blocking monoclonal antibody, with carboplatin and paclitaxel for the first-line treatment of adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC)....
Chemotherapy-Free Triplet in Previously Treated HR-Positive, HER2-Positive Advanced Breast Cancer
In a phase IIa study reported in The Lancet Oncology, Escrivá-de-Romani et al evaluated whether the chemotherapy-free triplet of the HER2-targeted bispecific antibody zanidatamab plus palbociclib and fulvestrant showed activity in heavily pretreated patients with hormone receptor (HR)-positive,...
Patient Advocacy Groups: Health-Care Programs Are Lifelines—Not Line Items
Forty nonprofit, nonpartisan organizations issued a statement this week to the House Energy & Commerce and Ways & Means Committees in regard to budget cuts and policy changes affecting Medicaid and health-care marketplaces. “As organizations representing millions of patients with serious...
Elective Nodal Radiotherapy for Oligorecurrent Nodal Prostate Cancer Metastases
In a phase II trial (PEACE V–STORM) reported in The Lancet Oncology, Ost et al found that elective nodal radiotherapy (ENRT) to the pelvis was associated with longer metastasis-free survival vs metastasis-directed therapy (MDT) in patients with pelvic nodal oligorecurrences of prostate cancer....
First-Line TFOX vs FOLFOX in Advanced HER2-Negative Gastric or Gastroesophageal Junction Adenocarcinoma
In a French phase III trial (PRODIGE 51-FFCD-GASTFOX) reported in The Lancet Oncology, Zaanan et al found that a modified FLOT (fluorouracil, oxaliplatin, and docetaxel) regimen known as TFOX (docetaxel, folinic acid, oxaliplatin, and fluorouracil) improved outcomes vs FOLFOX (folinic acid,...
NCCN Clinical Practice Guidelines in Oncology: 2025 Updates
The National Comprehensive Cancer Network (NCCN) released its first set of Clinical Practice Guidelines in Oncology (NCCN Guidelines®) in 1996, covering eight tumor types. Today, guidelines are available for more than 60 tumor types, subtypes, and related topics. During the NCCN’s 30th Annual...
Afatinib vs Chemotherapy in NSCLC With Uncommon Activating EGFR Mutations
In an interim analysis of a Japanese trial (ACHILLES/TORG1834) reported in the Journal of Clinical Oncology, Miura et al found that afatinib prolonged progression-free survival vs platinum-based chemotherapy in patients who had treatment-naive nonsquamous non–small cell lung cancer (NSCLC) with...
Overall Survival Analysis in CodeBreaK 300: Sotorasib Plus Panitumumab vs Investigator’s Choice in Chemorefractory KRAS G12C Colorectal Cancer
As reported in the Journal of Clinical Oncology by Pietrantonio et al, overall survival analysis in the phase III CodeBreaK 300 trial showed numeric improvement with sotorasib/panitumumab vs investigator's choice of treatment in patients with chemorefractory KRAS G12C-mutant metastatic colorectal...
CRISPR-Cas9-Edited TILs: Targeting Intracellular Immune Checkpoint CISH in Metastatic Colorectal Cancer
In a first-in-human, single-institution phase I trial reported in The Lancet Oncology, Lou et al found that autologous tumor-infiltrating lymphocytes (TILs) genetically edited with CRISPR-Cas9 to target the intracellular immune checkpoint CISH were tolerable and showed evidence of activity in...
In Case You Missed It: Additional Abstracts of Interest From AACR
Thousands of forward-looking research studies defined the 2025 American Association for Cancer Research (AACR) Annual Meeting. Here, aside from our fuller coverage of key presentations in The ASCO Post, we offer a snapshot of a few additional abstracts that may be of interest to cancer researchers...
Effects of Tumor-Infiltrating Clonal Hematopoiesis
In a study reported in The New England Journal of Medicine, Pich et al found that tumor-infiltrating clonal hematopoiesis (TI-CH) was associated with an increased risk of death or recurrence among patients with early-stage non–small cell lung cancer (NSCLC) and poorer overall survival among...
Early-Onset Breast, Colorectal, Endometrial, Pancreatic, and Kidney Cancers on the Rise
Recent studies have shown increasing rates of early-onset cancers, often defined as cancers occurring in people younger than age 50, especially colorectal, pancreatic, female breast, and uterine cancers, and younger birth cohorts seem to have a higher risk of some cancer types compared with older...
Remembering Roswell Park Leader Thomas B. Tomasi, Jr, MD, PhD
Thomas B. Tomasi, Jr, MD, PhD, who led Roswell Park Comprehensive Cancer Center as President and Chief Executive Officer from 1986 to 1996, died on March 23 at age 97. His tenure marked a renaissance at Roswell Park that elevated it to a place among the nation’s top cancer centers. The pinnacle of ...
Final Overall Survival Data: Amivantamab-vmjw Plus Lazertinib vs Osimertinib in EGFR-Mutated Non–Small Cell Lung Cancer
The phase III MARIPOSA trial was a head-to-head comparison of the EGFR tyrosine kinase inhibitor osimertinib and the combination of the bispecific EGF receptor–directed and MET receptor–directed monoclonal antibody amivantamab-vmjw and the EGFR tyrosine kinase inhibitor lazertinib in the first-line ...
Study Shows Disparities in Diagnosing Endometrial Cancer in Women With Postmenopausal Bleeding
Angela Nolin, MD, a gynecologic oncology fellow at Duke University Health System in Durham, North Carolina, and colleagues conducted a multi-institutional study to determine whether racial differences in transvaginal ultrasound efficacy combined with timely receipt of indicated endometrial...
Quick Takes on Research Findings on Novel Therapies for Gynecologic Cancers
The 2025 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer advanced the field with updates of practice-changing trials and other research that challenges the conventional approaches to treating gynecologic cancers. We have briefly captured some of that research here for readers ...
Survival Trends in Melanoma Brain Metastases: Update of Melanoma Graded Prognostic Assessment
In a study reported in Journal of Clinical Oncology, Sperduto and colleagues analyzed trends in survival associated with newly diagnosed melanoma brain metastases and updated the Melanoma Graded Prognostic Assessment (GPA). Study Details The study involved retrospective data from...
Outcomes With HSCT in Pediatric High-Risk AML
In a Children’s Oncology Group (COG) study (AAML1831) reported in Journal of Clinical Oncology, Huang et al found that hematopoietic stem cell transplantation (HSCT) was associated with improved outcomes in pediatric patients with high-risk acute myeloid leukemia (AML). Study Details The study...
Everolimus Plus Lanreotide vs Everolimus Alone in Aggressive Gastroenteropancreatic Neuroendocrine Tumors
In patients with aggressive gastroenteropancreatic neuroendocrine tumors, first-line treatment with the mTOR inhibitor everolimus and the somatostatin analog lanreotide more than doubled the median progression-free survival for patients vs everolimus alone, in the phase III JCOG1901 (STARTER-NET)...
Symptoms Preceding Unplanned Acute Care in Patients With Cancer
In a single-institution cohort study reported in JAMA Network Open, Chang et al identified patterns of symptoms preceding unplanned acute care encounters for patients with cancer. Study Details The study involved data from all unplanned acute care encounters (emergency department visits and...
Molecular Profiling May Optimize Treatment for Endometrial Cancer
A major international study, PORTEC-4a, provides evidence that molecular profiling may safely reduce the need for radiotherapy in some women with early-stage endometrial cancer while identifying those who would benefit from more intensive treatment. The results, presented at ESTRO 2025, may mark a...
Anal Cancer Rates Rising Most Among Older White and Hispanic Women
Anal cancer has been steadily increasing in the United States, with the biggest jumps among older women, especially White and Hispanic women, a new study presented at Digestive Disease Week 2025 (Abstract 76) found. According to the investigators, this shift challenges assumptions about high-risk...
Association for Clinical Oncology: Proposed Changes to Federal Health Agencies Threaten Future Cancer Research Advancements
The Association for Clinical Oncology is carefully reviewing the Administration’s Fiscal Year 2026 (FY 2026) budget proposal, which was released on May 2 and contains significant cuts to federal health agencies under the Department of Health and Human Services (HHS), notably a 40% cut to the...
Addition of Perioperative Pembrolizumab to Standard of Care in Newly Diagnosed Locally Advanced Head and Neck Cancer
In the phase III KEYNOTE-689 trial, perioperative use of the PD-1 inhibitor pembrolizumab given with standard therapy significantly improved event-free survival in newly diagnosed, previously untreated patients with locally advanced head and neck squamous cell carcinoma, researchers reported at the ...
Dose Escalation of Fluorodeoxyglucose PET–Guided Radiotherapy for Locally Advanced NSCLC
In an analysis from the Scandinavian phase III NARLAL2 trial, reported in the Journal of Clinical Oncology, Schytte et al found that fluorodeoxyglucose (FDG)-PET–guided heterogeneously dose-escalated radiotherapy was not associated with greater 6-month toxicity vs standard radiotherapy in...
Adavosertib in Recurrent or Persistent Uterine Serous Carcinoma
In the phase IIb ADAGIO trial, reported in the Journal of Clinical Oncology, Liu et al found that the Wee1 inhibitor adavosertib showed some activity in patients with recurrent or persistent uterine serous carcinoma. However, its use was associated with high toxicity rates. Study Details In the...
Cannabis Use Disorder Significantly Increases Mortality Risk in Colorectal Cancer
Patients with colorectal cancer and a history of cannabis use disorder had a more than 20 times higher risk of mortality within 5 years than those without cannabis use order, according to the results of a study published in Annals of Epidemiology. The 5-year mortality rate in patients with a...
AACR 2025: Novel CAR T-Cell Therapy Induces Response in Patients With Advanced Thyroid Cancers
A novel chimeric antigen receptor (CAR) T-cell therapy called AIC100, which targets the ICAM-1 protein, demonstrated encouraging responses and an acceptable safety profile in patients with two types of advanced thyroid cancer. Results from a small, first-in-human phase I trial were presented at the ...
DDW 2025: 20-Year Screening Program Drives Down Colorectal Cancer Cases, Deaths
A 20-year initiative that offered flexible options for colorectal cancer screening at a major integrated health system doubled colorectal cancer screening rates, cut cancer incidence by a third, halved deaths, and brought racial differences in outcomes to nearly zero, according to a study that will ...
DDW 2025: Genetic Mutations Linked to Worse Stomach Cancer Outcomes
Using next-generation DNA sequencing, researchers have identified four specific genes whose mutations are linked to the development and progression of lethal stomach cancers. This could potentially enable practitioners to offer targeted treatments that would spare many patients from unnecessarily...
AACR 2025: Topical BRAF Inhibitor Under Study for Managing Acneiform Rash
Compared with a placebo gel, an investigational topical BRAF inhibitor (LUT014) was found to improve the symptoms of acneiform rash in patients with colorectal cancer. These phase II clinical trial results were presented by Anisha B. Patel, MD, Associate Professor of Dermatology, Deputy Chair of...
